T-helper cells that produce interleukin-17 (T H 17 cells) are a recently identified CD4 1 T-cell subset with characterized pathological roles in autoimmune diseases [1] [2] [3] . The nuclear receptors retinoic-acid-receptor-related orphan receptors a and ct (RORa and RORct, respectively) have indispensible roles in the development of this cell type [4] [5] [6] [7] . Here we present SR1001, a high-affinity synthetic ligand-the first in a new class of compound-that is specific to both RORa and RORct and which inhibits T H 17 cell differentiation and function. SR1001 binds specifically to the ligand-binding domains of RORa and RORct, inducing a conformational change within the ligand-binding domain that encompasses the repositioning of helix 12 and leads to diminished affinity for co-activators and increased affinity for co-repressors, resulting in suppression of the receptors' transcriptional activity. SR1001 inhibited the development of murine T H 17 cells, as demonstrated by inhibition of interleukin-17A gene expression and protein production. Furthermore, SR1001 inhibited the expression of cytokines when added to differentiated murine or human T H 17 cells. Finally, SR1001 effectively suppressed the clinical severity of autoimmune disease in mice. Our data demonstrate the feasibility of targeting the orphan receptors RORa and RORct to inhibit specifically T H 17 cell differentiation and function, and indicate that this novel class of compound has potential utility in the treatment of autoimmune diseases.
T H 17 cells are crucial effector cells implicated in the pathology of numerous autoimmune diseases, including multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease and systemic lupus erythematosis. These cells produce a number of cytokines, including interleukin-17 (IL-17), that are known to enhance inflammatory processes [1] [2] [3] . The discovery of T H 17 cells as critical mediators of autoimmune disorders provides a unique opportunity to develop focused therapeutics that act by inhibiting the function of these cells. An essential role for the nuclear receptors RORa and RORct has been established in the development of T H 17 cells. Both of these nuclear receptors are required for the full differentiation of naive CD4 1 T cells into T H 17 cells [4] [5] [6] [7] .
Members of the nuclear receptor superfamily are ligand-dependent transcription factors. A number of drugs used in the clinic have been developed that target several nuclear receptor superfamily members. Therefore, an attractive strategy for the development of novel therapeutics to treat T H 17-mediated autoimmune disorders is to target RORa and RORct with synthetic ligands that inhibit their activity, resulting in decreased T H 17 cell differentiation and/or function. However, RORs are generally characterized as orphan receptors with no well-characterized ligands, thus it is unclear whether this approach is viable.
We recently characterized the benzenesulphonamide liver X receptor (LXR) agonist T0901317 as a promiscuous ligand that modulates the activity of several nuclear receptors including RORa and RORc 8 . Although T0901317 is a very potent and efficacious agonist of LXR, it also acts as an inverse agonist of RORa and RORc by suppressing their basal transcriptional activity 8 . Using the T0901317 scaffold as a lead compound we developed a derivative, SR1001 ( Fig. 1a and Supplementary Fig. 1 ), that was devoid of all LXR activity yet retained its ability to suppress the activity of RORa and RORc. We found that SR1001 repressed both GAL4-RORa and GAL4-RORc transcriptional activity in a dose-dependent manner ( Fig. 1b ), but demonstrated no effect on LXRa activity ( Fig. 1b) . We assessed the specificity of SR1001 in a panel comprising all 48 human nuclear receptors in a cell-based cotransfection assay 8 and did not observe activity on receptors other than RORa or RORc (data not shown). We examined the direct binding of SR1001 to RORa and RORc using competitive radioligand binding assays. SR1001 dose-dependently displaced [ 3 H]25hydroxycholesterol binding to RORa and RORc (inhibition constant (K i ) 5 172 and 111 nM, respectively) ( Fig. 1c ) but demonstrated no binding to RORb (data not shown).
We examined whether SR1001 would affect RORa-and RORcdependent regulation of an Il17 promoter-driven luciferase reporter 9 . HEK293 cells were transfected with the Il17 reporter and either fulllength RORa or RORc and treated with SR1001 or vehicle. As shown in Fig. 1d , SR1001 dose-dependently suppressed the Il17 promoterdriven activity by each of the receptors. Because SR1001 bound RORa and RORc, resulting in suppression of each receptor's transcriptional activity, we expected that SR1001 would inhibit co-activator binding to the receptors. SR1001 reduced the interaction of a co-activator TRAP220 nuclear receptor box 2 peptide with RORc in a dosedependent manner ( Fig. 1e ) (half-maximum inhibitory concentration (IC 50 ) value of ,117 nM). Collectively, these data demonstrate that SR1001 functions as an inverse agonist ligand of RORa and RORc.
Next, we determined whether SR1001 affected endogenous Il17a gene expression. The EL4 murine tumour cell line constitutively expresses RORa (encoded by Rora), RORct (Rorc) and IL-17A (Il17a) 10 . EL4 cells were treated with either control short interfering RNA (siRNA) or a mixture of RORa/c siRNA followed by treatment with either vehicle or SR1001. Reduction in the expression of RORa and RORct significantly reduced the expression of Il17a messenger RNA as measured by quantitative polymerase chain reaction (PCR) ( Fig. 2a ). More importantly, treatment of cells with SR1001 suppressed Il17a mRNA expression whereas treatment of RORa/c-depleted cells displayed a significantly blunted response, indicating that SR1001 suppression of Il17a mRNA expression is RORa/RORc dependent ( Fig. 2a ). Furthermore, SR1001 suppressed the expression of the RORa and RORc target gene G6PC in HepG2 cells, a human hepatocellular carcinoma cell line, providing further proof that the effect of SR1001 is mediated by RORa and RORc ( Supplementary Fig. 2) 11, 12 .
We hypothesized that SR1001 would inhibit binding of the coactivator SRC2 to either RORa or RORc when these receptors are occupying the Il17 promoter. We performed a sequential chromatin immunoprecipitation assay (ChIP-reChIP) assessing the relative amount of SRC2 associated with either RORa or RORc resident at the Il17 promoter in EL4 cells. SR1001 suppressed the ability of SRC2 to bind to RORa and RORc at the Il17 promoter and increased the recruitment of the co-repressor NCoR (Fig. 2b , lanes 3 and 4 and Fig. 2c, lanes 3 and 4) . Thus, SR1001 suppresses Il17a expression by directly inhibiting co-activator binding and promoting the recruitment of co-repressors to RORa and RORc.
To understand how ligand mediates the transcriptional activation of RORc, we performed comprehensive differential hydrogen-deuterium exchange mass spectrometry (HDX) analysis of the RORc ligandbinding domain (LBD) in the presence and absence of SR1001. This approach provides a measure of the localized ligand-induced perturbation in the conformational ensemble of the receptor. HDX kinetics of peptic peptides derived from the RORc LBD were measured and the average difference in the percentage of incorporated deuterium between apo RORc LBD and SR1001-bound RORc LBD is presented in Supplementary Fig. 3 . A negative value represents an increase in protection to exchange (more stable, less dynamic) in that region of the LBD when bound to ligand as compared to apo, whereas a positive value represents a decrease in protection to exchange (less stable, more dynamic). HDX kinetics are sensitive to hydrogen bond networks, and perturbations in these networks upon ligand binding can be determined using differential HDX. The differential HDX induced by SR1001 binding to RORc correlates with the co-crystal structure of RORc in complex with the sterol ligand 25-hydroxycholesterol (25-OHC; Protein Data Bank (PDB) 3LOL) 13 ( Supplementary Fig. 4 ). In the RORc-25-OHC structure, the C25 hydroxyl tail is oriented towards helix 11 (H11) and the A ring towards H1 and H2. As can be inferred from the RORc-25-OHC structure (PDB 3LOL), the hydroxyl group at the C1 position of 25-OHC is hydrogen bonded to Gln 286 (H1) and the 25-hydroxyl is hydrogen bonded to His 479 (H11). The regions within the RORc LBD that show increased protection to exchange upon binding of SR1001 include portions of H1 and H11. To highlight this, the HDX data in Supplementary Fig. 3 are represented graphically by overlay onto the structure of RORc-25-OHC (PDB 3LOL) with SR1001 docked (Fig. 2d) . Consistent with the differential HDX data, docking of SR1001 to RORc-25-OHC (PDB 3LOL) indicates a similar binding mode for SR1001 to RORc ( Supplementary Fig. 4) .
To examine the role of SR1001 in the modulation of this interaction between SRC2 and RORc, we performed differential HDX on RORc LBD in the presence and absence of the receptor interaction domain (RID) of SRC2 ( Fig. 2d and Supplementary Fig. 3 ), which contains three nuclear receptor boxes (,18 kDa). Several regions of the LBD demonstrate reduced HDX kinetics in the presence of SRC2 RID, 
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indicating an interaction between the two proteins. One region that is stabilized is H12, containing the AF2 domain of the receptor, which has been shown to be important for nuclear receptor interaction with co-activators. Furthermore, differential HDX analysis of the RORc-SRC2 complex in the presence and absence of SR1001 clearly demonstrates that ligand disrupts the receptor's interaction with SRC2 RID (Fig. 2d) . These data provide strong mechanistic insight into how inverse agonists such as SR1001 repress transcriptional output of RORc target genes. Because RORa and RORct activity is required for optimal T H 17 cell development 4 , we explored whether SR1001 would inhibit T H 17 cell differentiation. Splenocytes were cultured under T H 17 polarizing conditions (TGF-b and IL-6) with SR1001 or vehicle control for 5 days. The combination of TGF-b and IL-6 increased the mRNA expression of Il17a, Il17f, Il21 and Il22 in vehicle-treated cells, whereas SR1001treated cells failed to significantly upregulate these cytokines (Fig. 3) . Propidium iodide staining indicated that SR1001 was not toxic and did not induce cell death ( Supplementary Fig. 5 ). T H 17 cells and inducible T-regulatory cells (inducible T reg ) are both dependent on TGF-b for their differentiation. We evaluated whether expression of the T regspecific transcription factor Foxp3 was affected by SR1001 treatment.
Similar to vehicle control, Foxp3 mRNA expression was unaffected by SR1001 treatment, indicating that inhibition of T H 17 cell differentiation by SR1001 did not drive the cells into an inducible T reg phenotype ( Supplementary Fig. 6) 9 . Furthermore, suppression of T H 17 cell development with SR1001 treatment did not drive the splenocyte cultures into any of the other T-helper lineages, T H 1 or T H 2, as indicated by the decrease in Tbx21 (T-bet) and Gata3 mRNA expression, respectively ( Supplementary Fig. 6 ).
Finally, we explored whether SR1001 would inhibit IL-17 protein production and secretion. Splenocytes were cultured under T H 17 polarizing conditions and analysed for IL-17 expression by intracellular flow cytometry. Treatment with SR1001 inhibited the expression of IL-17 from CD4 1 T cells at day 4, 5 and 6 (Fig. 4a ). Similar to splenocyte cultures, intracellular flow cytometry demonstrated that SR1001 significantly repressed IL-17 expression in purified differentiated murine CD4 1 T cells (CD4 1 CD25 2 CD62L hi CD44 lo ) (Fig. 4b ).
Next we assessed the effect of SR1001 on IL-17 secretion from splenocyte cultures by enzyme-linked immunosorbent assay (ELISA). Treatment with SR1001 inhibited IL-17 secretion over a 3-day time course, when SR1001 was added at either the initiation of T H 17 cell differentiation (initiation) or 48 h after initiation of differentiation (post) (Fig. 4c ). SR1001 was also effective at inhibiting intracellular IL-17 expression in human peripheral blood mononuclear cells (PBMCs) (Fig. 4d ). Finally, we examined the effects of SR1001 on other T-helper cell lineages. Differentiation of T H 1, T H 2 and inducible T reg cells was unaffected by SR1001 treatment, as similar amounts of interferon (IFN)-c, IL-4, or Foxp3, respectively, were expressed compared to vehicle controls, indicating that SR1001 specifically targets T H 17 cells ( Supplementary Fig. 7) .
Given that RORa and RORct are required for the development of T H 17-mediated autoimmune diseases 4, 5 and that SR1001 inhibits the activity of both of these receptors leading to suppressed T H 17 cell development in vitro, we evaluated the effects of SR1001 treatment in an animal model of multiple sclerosis, experimental autoimmune encephalomyelitis (EAE), a well characterized model of T H 17-cellmediated autoimmune disease 14, 15 . After myelin oligodendrocyte glycoprotein (MOG 35-55 ) immunization at day 0, mice were treated with 25 mg kg 21 of SR1001 twice per day intraperitoneally for the duration of the study. As shown in Fig. 4e, SR1001 
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and Il22 mRNA expression ( Fig. 4f ). Intracellular cytokine analysis of splenocytes indicated a significant reduction in IL-17 expression and reduced total CD4 1 T cells with no effect on CD8 1 T cells. Messenger RNA expression of IL-4 and IFN-c was unaffected in both spleen and spinal cord ( Supplementary Fig. 8 ). These data are consistent with our interpretation that SR1001 suppresses EAE through its effects on T H 17 cell function in vivo. Further optimization of SR1001 may yield compounds with greater activity. Although RORa and RORct expression and activity are essential for full T H 17 cell development, it is important to note that RORa and RORc have roles outside of the immune system and are critical regulators of hepatic metabolism. Administration of SR1001 to C57BL/6 mice suppressed the expression of hepatic ROR target genes Cyp7b1, Nr1d1 (also called Rev-erba) and Serpine1 (also called PAI-1), indicating that this class of compound may have metabolic effects; however, we noted no obvious toxicity in animals treated with SR1001 (Supplementary Fig. 9 ) [16] [17] [18] .
We describe a novel, first-in-class, highly selective drug targeting the orphan nuclear receptors RORa and RORc that effectively suppresses T H 17 cell differentiation and cytokine expression and reduces the severity of disease in an animal model of multiple sclerosis. Our data indicate that the targeting of T H 17 cells, by blocking RORa/c function with a synthetic ligand, is a tractable approach for potential therapeutic intervention. Current treatments for T H 17-mediated autoimmune diseases, including multiple sclerosis, use agents that are general immunosuppressants and thus the side-effect profile is significant. Clearly, our data demonstrate that by targeting RORa and RORc one can specifically inhibit T H 17 cells without affecting other T-helper cell lineages, thereby providing a more focused therapy that will not be a general immunosuppressant. Therefore, SR1001 and derivatives of this compound may represent a novel class of superior drugs to not only treat T H 17-mediated autoimmune disorders but ROR-mediated metabolic disorders as well.
METHODS SUMMARY
For the synthesis of SR1001 (N-(5-(N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl)sulphamoyl)-4-methylthiazol-2-yl)acetamide), a solution of 2-(4aminophenyl)-1,1,1,3,3,3-hexafluoropropan-2-ol (0.88 g, 3.4 mmol), 2-acetamido-4-methylthiazole-5-sulphonyl chloride (0.79 g, 3.1 mmol) in acetone (15 ml) and 2,6-lutidine (0.73 ml, 6.2 mmol) was warmed to 60 uC for 18 h. The reaction was judged complete by analytical HPLC (starting materials consumed).
